Literature DB >> 30292634

IL-23 production of liver inflammatory macrophages to damaged hepatocytes promotes hepatocellular carcinoma development after chronic hepatitis B virus infection.

Mengya Zang1, Yuan Li2, Huan He1, Huiguo Ding3, Kun Chen1, Jun Du1, Taoyang Chen4, Zhiyuan Wu1, Hui Liu3, Dongmei Wang1, Jianqiang Cai5, Chunfeng Qu6.   

Abstract

Liver inflammation after chronic hepatitis B virus (HBV) infection is essential for hepatocellular carcinoma (HCC) development. We did a nested case-control study based on QBC chronic HBV infection cohort to identify HCC-related inflammatory cytokines. Serum levels of distinct Th-cell representative cytokines at varied periods before HCC diagnosis were determined in 50 HCC cases and 150 age- and gender-matched controls who did not develop HCC in 8-10 years. The individuals with HCC outcome had statistically higher serum levels of IL-23 than controls (P < 0.01). Further analysis in HCC tissues showed that CD14+ inflammatory macrophages were the major IL-23 producers. Monocytes-derived macrophages generated more amount of IL-23 after being stimulated with cell-associated HBV core antigen from damaged HBV-infected hepatocytes than the cells being stimulated with HBV-S and HBV e antigen, which are secreted from infected hepatocytes. IL-23 upregulated IL-23 receptor expressions on macrophages, enhanced macrophage-mediated angiogenesis. In HBV-transgenic (Alb1HBV) mice, administration of diethylnitrosamine induced more liver tumors than in wild-type mice. The livers of Alb1HBV mice had higher concentrations of IL-23 and vascular endothelial growth factor (VEGF) than the wild-type mice. Neutralizing IL-23 activity, diethylnitrosamine-treated Alb1HBV mice developed significantly less tumors and produced less VEGF, tumor angiogenesis was inhibited with dramatically decreased CD31+ cells within tumor mass (all P < 0.01).
CONCLUSION: Persistent IL-23 generation of liver inflammatory macrophages responding to damaged hepatocytes after chronic HBV infection altered macrophage function for HCC promotion. Blocking IL-23 activity might be helpful for the intervention in chronic hepatitis B patients who had high risk to HCC.
Copyright © 2018 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Hepatitis B virus proteins; Hepatocellular carcinoma; Interleukin 23; Liver macrophages

Mesh:

Substances:

Year:  2018        PMID: 30292634     DOI: 10.1016/j.bbadis.2018.10.004

Source DB:  PubMed          Journal:  Biochim Biophys Acta Mol Basis Dis        ISSN: 0925-4439            Impact factor:   5.187


  13 in total

1.  Role of Th17 Cytokines in the Liver's Immune Response during Fatal Yellow Fever: Triggering Cell Damage Mechanisms.

Authors:  Marcos Luiz Gaia Carvalho; Luiz Fábio Magno Falcão; Jeferson da Costa Lopes; Caio Cesar Henriques Mendes; Fábio Alves Olímpio; Vanessa do Socorro Cabral Miranda; Lais Carneiro Dos Santos; Daniel Dias Pinheiro de Moraes; Marcos Virgilio Bertonsin Filho; Luccas Delgado da Costa; Raimunda do Socorro da Silva Azevedo; Ana Cecília Ribeiro Cruz; Vanessa Costa Alves Galúcio; Lívia Caricio Martins; Maria Irma Seixas Duarte; Arnaldo Jorge Martins Filho; Jorge Rodrigues de Sousa; Pedro Fernando da Costa Vasconcelos; Juarez Antônio Simões Quaresma
Journal:  Cells       Date:  2022-06-28       Impact factor: 7.666

2.  Mechanism of HBV-positive liver cancer cell exosomal miR-142-3p by inducing ferroptosis of M1 macrophages to promote liver cancer progression.

Authors:  Zongqiang Hu; Hui Zhang; Wei Liu; Yanfeng Yin; Jie Jiang; Chuntao Yan; Yiting Wang; Li Li
Journal:  Transl Cancer Res       Date:  2022-05       Impact factor: 0.496

Review 3.  Macrophages and hepatocellular carcinoma.

Authors:  Zhiqiang Tian; Xiaojuan Hou; Wenting Liu; Zhipeng Han; Lixin Wei
Journal:  Cell Biosci       Date:  2019-09-26       Impact factor: 7.133

Review 4.  Tumor-Associated Macrophages in Hepatocellular Carcinoma Pathogenesis, Prognosis and Therapy.

Authors:  Konstantinos Arvanitakis; Triantafyllia Koletsa; Ioannis Mitroulis; Georgios Germanidis
Journal:  Cancers (Basel)       Date:  2022-01-04       Impact factor: 6.639

Review 5.  Cytokines and Chemokines in HBV Infection.

Authors:  Shihong Zhong; Tianling Zhang; Libo Tang; Yongyin Li
Journal:  Front Mol Biosci       Date:  2021-12-02

Review 6.  Immunopathology of Chronic Hepatitis B Infection: Role of Innate and Adaptive Immune Response in Disease Progression.

Authors:  Arshi Khanam; Joel V Chua; Shyam Kottilil
Journal:  Int J Mol Sci       Date:  2021-05-23       Impact factor: 5.923

7.  Cryptolepine inhibits hepatocellular carcinoma growth through inhibiting interleukin-6/STAT3 signalling.

Authors:  Seth A Domfeh; Patrick W Narkwa; Osbourne Quaye; Kwadwo A Kusi; Gordon A Awandare; Charles Ansah; Alimatu Salam; Mohamed Mutocheluh
Journal:  BMC Complement Med Ther       Date:  2021-06-02

8.  Identification of hepatitis B virus and liver cancer bridge molecules based on functional module network.

Authors:  Xiao-Bing Huang; Yong-Gang He; Lu Zheng; Huan Feng; Yu-Ming Li; Hong-Yan Li; Feng-Xia Yang; Jing Li
Journal:  World J Gastroenterol       Date:  2019-09-07       Impact factor: 5.374

9.  A murine cellular model of necroinflammation displays RAGE-dependent cytokine induction that connects to hepatoma cell injury.

Authors:  Malte Bachmann; Laura Lamprecht; Sina Gonther; Josef Pfeilschifter; Heiko Mühl
Journal:  J Cell Mol Med       Date:  2020-07-22       Impact factor: 5.310

Review 10.  Targeting tumor-associated macrophages to synergize tumor immunotherapy.

Authors:  Xiaonan Xiang; Jianguo Wang; Di Lu; Xiao Xu
Journal:  Signal Transduct Target Ther       Date:  2021-02-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.